Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Toll Brothers Inc.

25.4% sales growth and 8.89% return on equity

Toll Brothers, Inc., together with its subsidiaries, designs, builds, markets, sells, and arranges finance for detached and attached homes in luxury residential communities in the United States.

Toll Brothers Inc. sales growth this year is anticipated to be 17.2% and 10.1% for next year.

Year-on-year quarterly revenue growth grew by 7%, now sitting on 7.08B for the twelve trailing months.

Toll Brothers Inc.’s sales growth for the next quarter is 25.4%. The company’s growth estimates for the ongoing quarter and the next is 14.6% and 55.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.89%.

Toll Brothers Inc.’s Stock Top and Bottom Yearly Value

Toll Brothers Inc.’s stock is valued at $44.39 at 01:57 EST, way below its 52-week high of $50.42 and way higher than its 52-week low of $13.28.

Toll Brothers Inc.’s Moving Average

Toll Brothers Inc.’s worth is below its 50-day moving average of $45.71 and higher than its 200-day moving average of $41.27.

2. Futu Holdings Limited

149.2% sales growth and 20.42% return on equity

Futu Holdings Limited operates digitized brokerage and wealth management platform in Hong Kong, China, the United States, and internationally.

Futu Holdings Limited sales growth this year is expected to be 170.2% and 51.5% for next year.

Year-on-year quarterly revenue growth grew by 281.7%, now sitting on N/A for the twelve trailing months.

Futu Holdings Limited’s sales growth for the next quarter is 149.2%. The company’s growth estimates for the present quarter and the next is 100% and negative -40%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.42%.

Futu Holdings Limited’s Stock Top and Bottom Yearly Value

Futu Holdings Limited’s stock is valued at $41.15 at 01:57 EST, way under its 52-week high of $51.10 and way higher than its 52-week low of $8.16.

Futu Holdings Limited’s Moving Average

Futu Holdings Limited’s worth is above its 50-day moving average of $38.00 and way higher than its 200-day moving average of $30.45.

3. FNF Group of Fidelity National Financial, Inc.

44.4% sales growth and 16.02% return on equity

Fidelity National Financial, Inc., together with its subsidiaries, provides various insurance products in the United States.

FNF Group of Fidelity National Financial, Inc. sales growth this year is anticipated to be 13.1% and 1.8% for next year.

Year-on-year quarterly revenue growth grew by 32.8%, now sitting on 9.38B for the twelve trailing months.

FNF Group of Fidelity National Financial, Inc.’s sales growth for the next quarter is 44.4%. The company’s growth estimates for the present quarter and the next is 20% and 16.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.02%.

FNF Group of Fidelity National Financial, Inc.’s Stock Top and Bottom Yearly Value

FNF Group of Fidelity National Financial, Inc.’s stock is valued at $37.08 at 01:57 EST, way under its 52-week high of $49.28 and way above its 52-week low of $19.00.

FNF Group of Fidelity National Financial, Inc.’s Moving Average

FNF Group of Fidelity National Financial, Inc.’s value is above its 50-day moving average of $34.43 and way higher than its 200-day moving average of $33.03.

4. BMC Stock Holdings, Inc.

12.8% sales growth and 12.69% return on equity

BMC Stock Holdings, Inc., together with its subsidiaries, provides various building products and services for homebuilder and professional contractor customers in the United States.

BMC Stock Holdings, Inc. sales growth this year is expected to be 14.2% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 3.88B for the twelve trailing months.

BMC Stock Holdings, Inc.’s sales growth for the next quarter is 12.8%. The company’s growth estimates for the present quarter and the next is 86.5% and 45%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.69%.

BMC Stock Holdings, Inc.’s Stock Top and Bottom Yearly Value

BMC Stock Holdings, Inc.’s stock is valued at $46.17 at 01:57 EST, below its 52-week high of $50.26 and way higher than its 52-week low of $13.38.

BMC Stock Holdings, Inc.’s Moving Average

BMC Stock Holdings, Inc.’s worth is higher than its 50-day moving average of $44.70 and way above its 200-day moving average of $35.17.

5. Bank First Corporation

17.7% sales growth and 13.29% return on equity

Bank First Corporation operates as a holding company for Bank First N.A.

Bank First Corporation sales growth this year is expected to be 26.9% and a negative 3.1% for next year.

Year-on-year quarterly revenue growth grew by 30.5%, now sitting on 94.53M for the twelve trailing months.

Bank First Corporation’s sales growth for the next quarter is 17.7%. The company’s growth estimates for the current quarter and the next is 26.9% and 35.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.29%.

Bank First Corporation’s Stock Top and Bottom Yearly Value

Bank First Corporation’s stock is valued at $69.26 at 01:57 EST, under its 52-week high of $70.01 and way higher than its 52-week low of $43.63.

Bank First Corporation’s Moving Average

Bank First Corporation’s value is above its 50-day moving average of $65.80 and above its 200-day moving average of $62.99.

6. Fresenius Medical Care AG

12.3% sales growth and 12.23% return on equity

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally.

Fresenius Medical Care AG sales growth this year is anticipated to be 10.7% and 4.1% for next year.

Year-on-year quarterly revenue growth declined by 0.1%, now sitting on N/A for the twelve trailing months.

Fresenius Medical Care AG’s sales growth for the next quarter is 12.3%. The company’s growth estimates for the present quarter and the next is 2.7% and 30.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.23%.

Fresenius Medical Care AG’s Stock Top and Bottom Yearly Value

Fresenius Medical Care AG’s stock is valued at $41.55 at 01:57 EST, way below its 52-week high of $46.55 and way higher than its 52-week low of $29.17.

Fresenius Medical Care AG’s Moving Average

Fresenius Medical Care AG’s value is above its 50-day moving average of $41.50 and below its 200-day moving average of $42.55.

7. Genmab A/S

47.1% sales growth and 36.46% return on equity

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark.

Genmab A/S sales growth this year is anticipated to be 99.4% and a negative 20.4% for next year.

Year-on-year quarterly revenue growth grew by 65.8%, now sitting on N/A for the twelve trailing months.

Genmab A/S’s sales growth for the next quarter is 47.1%. The company’s growth estimates for the ongoing quarter and the next is a negative 66.3% and 30%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.46%.

Genmab A/S’s Stock Top and Bottom Yearly Value

Genmab A/S’s stock is valued at $38.45 at 01:57 EST, under its 52-week high of $39.81 and way higher than its 52-week low of $16.24.

Genmab A/S’s Moving Average

Genmab A/S’s worth is higher than its 50-day moving average of $36.29 and above its 200-day moving average of $35.16.

LEAVE A REPLY

Please enter your comment!
Please enter your name here